Abstract
Background Rotavirus vaccine effectiveness (VE) is reduced among children in low-income countries (LICs). Indirect (transmission-mediated) effects of rotavirus vaccine may contribute to the total population impact of vaccination. We estimated the effectiveness of rotavirus vaccine in preventing transmission of rotavirus to household contacts in Blantyre, Malawi.
Methods We recruited vaccine-age-eligible children with acute rotavirus gastroenteritis (case-children), together with their household contacts. Clinical data and stool samples were collected from case-children at presentation, and prospectively from household contacts over 14 days. A single stool sample was collected from control households containing asymptomatic children age-matched to case-children. Samples were tested for rotavirus using real-time PCR. Risk factors for household transmission of rotavirus infection and clinical rotavirus disease were identified using logistic regression. Vaccine effectiveness against transmission (VET) was estimated as one minus the ratio of secondary attack rates (SAR) in vaccinated and unvaccinated populations, using VE estimates from the associated diarrhoeal surveillance platform to estimate the counterfactual SAR without vaccination.
Findings A total of 196 case-households and 55 control-households were recruited. Household SAR for rotavirus infection was high (65%); SAR for clinical disease was much lower (5%). Asymptomatic infection in control households was common (28%). Increasing disease severity was associated with increased risk of transmission of both rotavirus infection and disease to household contacts. Estimated VET was 39% (95% confidence interval 16-57%).
Interpretation Rotavirus vaccine has the potential to substantially reduce household rotavirus transmission. This should be considered in clinical and health economic assessments of vaccine impact.
Funding Wellcome Trust and NIH/NIAID.
Competing Interest Statement
LP, AB, BL: no conflict. NB-Z and K.C.J have received research grant support from GlaxoSmithKline Biologicals for work on rotavirus vaccines. MI-G has received research grant support from GlaxoSmithKline Biologicals and Sanofi Pasteur MSD for work on rotavirus. NAC has received research grant support and honoraria for participation in rotavirus vaccine advisory board meetings from GlaxoSmithKline Biologicals. V.E.P. is a member of the WHO Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC) and has received reimbursement from Merck for travel expenses to attend a Scientific Input Engagement unrelated to rotavirus vaccines
Funding Statement
This study was supported by two Wellcome Trust Clinical PhD Fellowships [grant numbers 102466/Z/13/A to AB and 102464/Z/13/A to LP], a Wellcome Trust Programme Grant [grant number 091909/Z/10/Z], the MLW Programme Core Grant Strategic Award [grant number 101113/Z/13/Z] and by the U.S. National Institutes of Health [grant number R01-AI112970 to VEP]. K.C.J. is supported by an International Wellcome Trust Training Fellowship (grant number: 201945/Z/16/Z)
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in manuscript will be made publically available via university data repository
